Vincent Medical Holdings Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Vincent Medical Holdings de 10.4% y 16.1% por año respectivamente. Se prevé que el BPA crezca en un 10.5% al año. Se espera que la rentabilidad financiera sea de 11.9% en 3 años.

Información clave

10.4%

Tasa de crecimiento de los beneficios

10.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	34.8%
Tasa de crecimiento de los ingresos	16.1%
Rentabilidad financiera futura	11.9%
Cobertura de analistas	Low
Última actualización	21 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Returns On Capital Are Showing Encouraging Signs At Vincent Medical Holdings (HKG:1612)

Dec 21

Vincent Medical Holdings (HKG:1612) Is Experiencing Growth In Returns On Capital

Aug 29

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

May 30

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

Dec 15

One Analyst Thinks Vincent Medical Holdings Limited's (HKG:1612) Revenues Are Under Threat

Aug 07

Downgrade: Here's How This Analyst Sees Vincent Medical Holdings Limited (HKG:1612) Performing In The Near Term

Jul 27

Is Vincent Medical Holdings (HKG:1612) A Risky Investment?

Jun 06

One Vincent Medical Holdings Limited (HKG:1612) Analyst Just Slashed Their Estimates By A Material 13%

Mar 28

Vincent Medical Holdings Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Mar 25

Vincent Medical Holdings (HKG:1612) Knows How To Allocate Capital

Mar 23

Have Insiders Been Buying Vincent Medical Holdings Limited (HKG:1612) Shares This Year?

Mar 04

I Ran A Stock Scan For Earnings Growth And Vincent Medical Holdings (HKG:1612) Passed With Ease

Feb 17

Is There An Opportunity With Vincent Medical Holdings Limited's (HKG:1612) 42% Undervaluation?

Feb 04

What You Need To Know About Vincent Medical Holdings Limited's (HKG:1612) Investor Composition

Jan 22

Investors Who Bought Vincent Medical Holdings (HKG:1612) Shares A Year Ago Are Now Up 267%

Jan 08

Has Vincent Medical Holdings Limited's (HKG:1612) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Dec 26

What We Learned About Vincent Medical Holdings' (HKG:1612) CEO Compensation

Dec 14

Did Vincent Medical Holdings Limited (HKG:1612) Insiders Buy Up More Shares?

Dec 02

Can Vincent Medical Holdings (HKG:1612) Keep Up These Impressive Returns?

Nov 20

Previsiones de crecimiento de beneficios e ingresos

SEHK:1612 - Estimaciones futuras de los analistas y datos financieros pasados (HKD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1,165	78	76	96	1
12/31/2025	982	69	68	88	1
12/31/2024	834	62	65	85	1
12/31/2023	718	57	93	125	N/A
9/30/2023	714	55	81	105	N/A
6/30/2023	710	54	68	84	N/A
3/31/2023	669	18	63	80	N/A
12/31/2022	629	-17	57	76	N/A
9/30/2022	658	-21	78	98	N/A
6/30/2022	688	-26	100	120	N/A
3/31/2022	733	18	97	120	N/A
12/31/2021	778	61	94	119	N/A
9/30/2021	901	114	106	140	N/A
6/30/2021	1,024	167	118	162	N/A
3/31/2021	1,090	192	131	185	N/A
12/31/2020	1,155	217	144	208	N/A
9/30/2020	957	153	89	143	N/A
6/30/2020	758	90	34	79	N/A
3/31/2020	630	51	16	55	N/A
12/31/2019	502	12	-3	31	N/A
9/30/2019	505	22	10	40	N/A
6/30/2019	507	32	24	50	N/A
3/31/2019	498	31	15	42	N/A
12/31/2018	488	31	6	35	N/A
9/30/2018	478	22	-21	14	N/A
6/30/2018	468	14	-47	-8	N/A
3/31/2018	457	13	-43	-13	N/A
12/31/2017	446	13	-39	-18	N/A
9/30/2017	441	21	N/A	9	N/A
6/30/2017	435	29	N/A	36	N/A
3/31/2017	451	29	N/A	29	N/A
12/31/2016	467	29	N/A	22	N/A
9/30/2016	465	39	N/A	31	N/A
6/30/2016	462	48	N/A	40	N/A
3/31/2016	455	53	N/A	47	N/A
12/31/2015	448	58	N/A	55	N/A
12/31/2014	389	36	N/A	44	N/A
12/31/2013	324	23	N/A	41	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (10.4% al año) de 1612 es superior a la tasa de ahorro (2%).

Beneficios vs. Mercado: Se prevé que los beneficios (10.4% al año) de 1612 crezcan menos que el mercado Hong Kong (11.5% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 1612 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (16.1% al año) de 1612 crezcan más rápidamente que los del mercado Hong Kong (7.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 16.1% al año) de 1612 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 1612 sea baja dentro de 3 años (11.9%).

Vincent Medical Holdings Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Vincent Medical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Vincent Medical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Consensus revenue estimates fall by 18%

Vincent Medical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Price target decreased to HK$1.30

Consensus revenue estimates fall by 22%

Recent updates

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vincent Medical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.089 (vs HK$0.027 loss in FY 2022)

Vincent Medical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 21 June 2024

Vincent Medical Holdings Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

Vincent Medical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Executive Chairman recently bought HK$239k worth of stock

Returns On Capital Are Showing Encouraging Signs At Vincent Medical Holdings (HKG:1612)

CEO & Executive Director recently bought HK$120k worth of stock

Vincent Medical Holdings (HKG:1612) Is Experiencing Growth In Returns On Capital

Upcoming dividend of HK$0.013 per share at 6.0% yield

First half 2023 earnings released: EPS: HK$0.041 (vs HK$0.068 loss in 1H 2022)

New minor risk - Dividend sustainability

Vincent Medical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 29, 2023

New major risk - Revenue and earnings growth

Vincent Medical Holdings Limited to Report First Half, 2023 Results on Aug 23, 2023

Vincent Medical Holdings Limited Appoints Leung Ming Chu as Non-Executive Director

Executive Chairman recently bought HK$103k worth of stock

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

Vincent Medical Holdings Limited Announces Retirement of Guo Pengcheng as Non-Executive Director

Full year 2022 earnings: EPS exceeds analyst expectations

Vincent Medical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Vincent Medical Holdings Limited Announces FDA 510(K) Clearance of the Inspired Vhb20 Heated Humidifier

Vincent Medical Holdings Limited Announces Board Changes

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

Now 21% undervalued

Less than half of directors are independent

Executive Chairman recently bought HK$417k worth of stock

Upcoming dividend of HK$0.025 per share

Vincent Medical Holdings Limited Announces Special Dividend for the Six Months Ended June 30, 2022, Payable on September 30, 2022

First half 2022 earnings released: HK$0.068 loss per share (vs HK$0.064 profit in 1H 2021)

One Analyst Thinks Vincent Medical Holdings Limited's (HKG:1612) Revenues Are Under Threat

Consensus revenue estimates fall by 18%

Vincent Medical Holdings' (HKG:1612) Returns Have Hit A Wall

Vincent Medical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

VP of Engineering & Executive Director recently bought HK$58k worth of stock

Vincent Medical Holdings Limited Approves Final Dividend for the Year Ended 31 December 2021

Vincent Medical Holdings' (HKG:1612) Dividend Will Be Reduced To HK$0.025

Vincent Medical Holdings Limited Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.025 per share

Vincent Medical Holdings' (HKG:1612) Dividend Will Be Reduced To HK$0.025

Price target decreased to HK$1.30

Less than half of directors are independent

Vincent Medical Holdings (HKG:1612) Will Pay A Smaller Dividend Than Last Year

Executive Chairman recently bought HK$211k worth of stock

Consensus revenue estimates fall by 22%

Under The Bonnet, Vincent Medical Holdings' (HKG:1612) Returns Look Impressive

Vincent Medical Holdings Limited to Report Fiscal Year 2021 Results on Mar 23, 2022

Vincent Medical Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2021

Investor sentiment improved over the past week

VP of Engineering & Executive Director recently bought HK$53k worth of stock

Executive Chairman recently bought HK$70k worth of stock

Executive Chairman recently bought HK$240k worth of stock

Executive Chairman recently bought HK$237k worth of stock

Upcoming dividend of HK$0.02 per share

First half 2021 earnings released: EPS HK$0.064 (vs HK$0.14 in 1H 2020)

Investor sentiment deteriorated over the past week

Downgrade: Here's How This Analyst Sees Vincent Medical Holdings Limited (HKG:1612) Performing In The Near Term

Consensus revenue estimates fall to HK$795.0m

Investor sentiment deteriorated over the past week

Vincent Medical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2021

Is Vincent Medical Holdings (HKG:1612) A Risky Investment?

Price target increased to HK$4.80

Vincent Medical Holdings Limited Approves Final Dividend for the Year Ended December 31, 2020

Upcoming dividend of HK$0.11 per share

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS HK$0.34 (vs HK$0.018 in FY 2019)

CEO, GM & Executive Director exercised options to buy HK$2.5m worth of stock.